Skip to main content
Alleviate Labs
AboutRequest information

Evidence and updates

What supports the current claims?

External research provides context on product labels, liquid measurement, and prescription adherence. Separately, internal sources document a software demo using fictional example data. Neither establishes Bonsai performance or clinical outcomes.

Source-linkedExternal research ≠ product validationNot clinical proof

External research · not Bonsai results

External findings, with their limits.

Evidence boundaryExternal research describes different problems and populations, not Bonsai study results. Bonsai is pre-production; improved dosing accuracy, adherence, and outcomes have not been established.

Product label accuracy

40%

12 of 30 oral cannabis oils were outside the ±15% THC label tolerance.

Study context

Products sampled from the Ontario Cannabis Store, November 2021–January 2022.

Scope and limits.

Small, nonrepresentative sample—not all cannabis. This measured label accuracy, not delivered dose. Labels mostly overstated contents; this is not evidence of widespread excess THC.

Method
Laboratory analysis compared measured cannabinoid contents with the labels of 30 legal oral cannabis oil products sold in Ontario, Canada.
What this supports—and does not
A product label and measured contents are different evidence. This study did not test Bonsai and is not proof of Bonsai performance.

Measuring liquid medication

84.4%

Of 2,110 parents, 84.4% made at least one error across nine measured doses.

Study context

Parents of children aged 8 or younger in three US urban pediatric clinics; more than 20% deviation counted as an error.

Scope and limits.

This is the percentage of parents with at least one error—not the percentage of doses. It is not an adult cannabis study and does not establish a pediatric indication for Bonsai.

Method
A randomized experiment evaluated dosing tools and label units. Each parent measured nine doses; an error was a deviation of more than 20% from the intended amount.
What this supports—and does not
Cups had higher odds of dosing errors than oral syringes. This is established evidence about those tools, not a comparison with Bonsai or a claim that Bonsai is superior.

Following a prescription

About 50%

Of filled prescriptions are taken incorrectly with respect to timing, dosage, frequency, or duration.

Study context

A historical estimate cited in a CDC MMWR review published November 17, 2017.

Scope and limits.

The denominator is filled prescriptions, not people. This is a historical review estimate, not a present-day census or a cannabis-specific finding.

Method
The CDC review summarizes existing medication-adherence research; this estimate is not a new population-wide measurement.
What this supports—and does not
Adherence is affected by cost, access, instructions, and side effects. These barriers call for support, not blame. This review did not evaluate Bonsai.

Internal demo evidence and public notices.

These sources document internal demonstrations and a public notice, not independent clinical evidence. Dates show when each source was recorded.

  1. Internal demonstrationDemonstrated capability

    Plans, activity, and feedback in the demo

    The software separates the clinician’s plan, product information, simulated activity, and patient feedback. It does not validate hardware or establish intake or benefit.

    Source: How it works
  2. Internal product boundaryCurrent boundary

    Patient start and care-team access

    Bonsai would start locally within the clinician’s plan. Demo records become available to a linked care team after upload.

    Source: Safety and trust
  3. Public noticeCurrent information practice

    Marketing-site privacy notice

    The notice covers inquiry data, storage, retention, and privacy requests—not the separate product demos.

    Source: Privacy notice

Not established

What has not been established.

No Bonsai-specific validation established

  • Bonsai-specific external clinical studies or peer-reviewed validation
  • Customer, partner, testimonial, or patient outcome evidence
  • Certifications, regulatory clearances, or compliance attestations
  • Measurement, dosing, chemical-intake, treatment, or safety outcomes
  • Commercial availability, pricing, launch timing, or final specifications

Planned amounts do not measure intake. Patient reports are not verified outcomes.

How to read this page

Demonstrated is not validated.

A software example shows behavior. Hardware, safety, and clinical claims need separate evidence.

Demonstrated

Shown in the demo

The public software flow, its source labels, and its stated boundaries (not a physical device test).

External validation

Requires an approved source

A separately sourced study, device test, or attestation would need a stated scope before supporting a stronger claim.

Observational

Never presented as efficacy

Patient feedback can add context, but it cannot on its own prove benefit.